CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 214 enrolled
Drug / intervention
Sapien XT™ transcatheter heart valve and delivery systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00820599
NCT00820599N/ACompleted

Transfemoral Placement of AoRtic Balloon Expandable Transcatheter VAlves TrIaL (EUROPE)

Edwards Lifesciences·interventional·Posted Jan 12, 2009·Updated Nov 2, 2020

In Brief

A clinical study evaluating Sapien XT™ transcatheter heart valve and delivery system for Aortic Valve Stenosis. Completed, enrolled 214 participants across 11 sites in 4 countries.

Detailed Summary

A single arm, prospective multicenter non-randomized confirmatory clinical trial evaluating the Edwards SAPIEN XT™ transcatheter heart valve (model 9300TFX; "study valve"), its transfemoral delivery system, and crimper accessories. The trial includes a premarket confirmatory cohort to evaluate the system performance as well as a Post Market Clinical Follow-up phase involving expanded enrollment and long-term follow-up of all patients to evaluate valve performance out to 5 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, France, Germany, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 12, 2009
Enrollment StartDec 1, 2008
Primary CompletionDec 1, 2010
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 17.5 years ago

Interventions

Sapien XT™ transcatheter heart valve and delivery systemdevice